AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live

昨天

AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday.

Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said.

AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement.

Price: 259.59, Change: -2.12, Percent Change: -0.81

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2664870565"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664870565\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664870565?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664870565","market":"fut","top_or_hot":-1,"title":"AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints","media":"MT Newswires Live","content":"<html><body><p> AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday.</p><p>Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said.</p><p>AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement.</p><p>Price: 259.59, Change: -2.12, Percent Change: -0.81</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-03 22:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday.</p><p>Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said.</p><p>AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement.</p><p>Price: 259.59, Change: -2.12, Percent Change: -0.81</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443549.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664870565","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664870565","pubTimestamp":1788444473,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free sur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","PPH":"VanEck Pharmaceutical ETF","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","ABBV":"艾伯维公司","AGNG":"Global X Aging Population ETF","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","MEDX":"HORIZON KINETICS MEDICAL ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","PJP":"INVESCO PHARMACEUTICALS ETF","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","IXJ":"全球医疗业ETF-iShares","IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","TRUH":"VanEck Healthcare TruSector ETF","IYH":"iShares U.S. Healthcare ETF","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","XLV":"健康照护类股ETF-SPDR","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","FHLC":"Fidelity MSCI Health Care Index","RXL":"ProShares Ultra Health Care","BK4581":"高盛持仓","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","VHT":"Vanguard Health Care ETF","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"艾伯维依替他咪唑治疗多发性骨髓瘤的 3 期研究满足双主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":0.6,"RXL":0.6,"PJP":0.6,"PPH":0.6,"IYH":0.6,"ABBV":1.5,"FTXH":0.6,"AGNG":0.6,"IXJ":0.6,"TRUH":0.6,"JDOC":0.6,"MEDX":0.6,"GLAM":0.6,"VHT":0.6,"FHLC":0.6},"content_text":"AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free survival, the company said Thursday.Trial results, which covered 393 patients, demonstrated significantly higher objective response rate and improved progression-free survival with etentamig compared with standard available therapies, AbbVie said.AbbVie plans to discuss the phase 3 study's results with regulatory authorities globally to determine the next development steps for etentamig, according to the statement.Price: 259.59, Change: -2.12, Percent Change: -0.81","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}